Skip to main content
Menu
US

AlphaLISA Human KEAP1 Binding Kit, 500 Assay Points

The AlphaLISA™ Human KEAP1 Binding Kit is designed to screen and characterize compounds that specifically bind the E3 ligase, KEAP1, using Alpha Technology.

For research use only. Not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption, and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Feature Specification
Application Protein Quantification
Sample Volume 5 µL

The AlphaLISA™ Human KEAP1 Binding Kit is designed to screen and characterize compounds that specifically bind the E3 ligase, KEAP1, using Alpha Technology.

For research use only. Not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption, and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Product Variants
Unit Size: 500 Assay Points
Part #:
AL3194C
List Price
USD 3,338.00
Unit Size: 5,000 Assay Points
Part #:
AL3194F
List Price
USD 16,470.00

Overview

Kelch-like ECH-associated protein 1 (KEAP1) is an adaptor subunit of Cullin 3-based E3 ubiquitin ligase involved in oxidative stress response. By promoting UPS mediated degradation, KEAP1 controls the expression level of key proteins such as NRF2, a transcription factor controlling the expression of antioxidant proteins. Sustained activation of NRF2 has been associated to cancers resistance, and its inhibition has been shown to dampen drugs resistance. Targeted protein degradation (TPD) uses small molecules to recruit E3 ubiquitin ligases into the proximity of the targeted protein of interest, promoting its ubiquitination-dependent degradation. Exploiting KEAP1 inhibitors for the development of bifunctional Proteolysis-targeting chimeras (PROTACs) is expected to expand the toolbox of E3 ligases to removing undesired proteins (e.g., NRF2) involved in various diseases such as cancers, neurodegenerative diseases, and metabolic disorders.

Formats
  • Our 500 assay point kit allows you to run 500 wells in a 384-well format, using a 20 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in a 384-well format, using a 20 µL reaction volume (5 µL of sample).
Features
  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Small sample volume

Specifications

Application
Protein Quantification
Automation Compatible
Yes
Brand
AlphaLISA
Detection Modality
Alpha
Product Group
Kit
Sample Volume
5 µL
Shipping Conditions
Shipped in Blue Ice
Target
KEAP1
Target Class
Biomarkers
Technology
Alpha
Therapeutic Area
Oncology
Unit Size
500 Assay Points

Video gallery

Resources

Are you looking for resources, click on the resource type to explore further.

1-1 of 1 Resources
Flyer Icon
Flyer
Reagent solutions for targeted protein degradation

Proteolysis Targeting Chimaeras (PROTACs) are innovative small molecules that revolutionize drug discovery. They consist of two...

Scroll Icon